| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CD24A |
| WB Predicted band size | 8 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human CD24 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CD24抗体的3篇示例文献(内容为模拟概括，仅供参考)：
---
1. **文献名称**：*CD24作为肿瘤免疫逃逸的关键“别吃我”信号及其抗体阻断治疗潜力*
**作者**：Barkal AA 等
**摘要**：该研究发表于《自然》(*Nature*)，揭示了CD24在多种实体瘤(如卵巢癌、乳腺癌)中高表达，通过与巨噬细胞表面Siglec-10结合传递“别吃我”信号，帮助肿瘤逃避免疫清除。抗CD24抗体可阻断该通路，增强巨噬细胞对肿瘤细胞的吞噬作用，为免疫治疗提供新靶点。
2. **文献名称**：*抗CD24抗体靶向肿瘤干细胞抑制三阴性乳腺癌转移*
**作者**：Smith LM 等
**摘要**：研究显示CD24是乳腺癌干细胞的标志物，与其自我更新和转移能力相关。抗CD24抗体通过ADCC(抗体依赖的细胞毒性)作用特异性清除肿瘤干细胞，并在小鼠模型中显著抑制肿瘤生长和肺转移，提示其在靶向治疗中的应用潜力。
3. **文献名称**：*CD24-Fc融合蛋白缓解COVID-19相关过度炎症反应的机制研究*
**作者**：Chen GY 等
**摘要**：该研究发现CD24可调控先天免疫系统过度激活。在重症COVID-19患者中，使用CD24-Fc融合蛋白(模拟抗体功能)可抑制TLR通路介导的细胞因子风暴，降低炎症损伤，为治疗病毒感染引发的过度免疫反应提供新策略。
---
如需具体文献，建议通过PubMed或Google Scholar检索关键词“CD24 antibody”或“CD24 immunotherapy”获取最新研究。
CD24. a small glycosylphosphatidylinositol (GPI)-anchored cell surface protein, functions as a “don’t eat me” signal by interacting with Siglec-10 on immune cells, particularly macrophages, to suppress phagocytosis and dampen immune responses. Its overexpression in various cancers, including ovarian, breast, and hepatocellular carcinomas, is linked to immune evasion, metastasis, and poor prognosis. CD24 antibodies are designed to block this immunosuppressive interaction, thereby enhancing anti-tumor immunity by promoting phagocytosis of cancer cells.
Structurally, CD24 lacks transmembrane domains, relying on GPI anchors for membrane attachment. Its extracellular region contains heavily glycosylated motifs critical for ligand binding. Research highlights CD24’s role in modulating both innate and adaptive immunity, making it a compelling target for immunotherapy. Preclinical studies demonstrate that anti-CD24 antibodies synergize with existing therapies, such as anti-PD-1/PD-L1 agents, to improve tumor clearance. Beyond oncology, CD24 is implicated in autoimmune diseases and inflammatory conditions, where its inhibition may mitigate excessive immune activation. For instance, CD24-Fc fusion proteins have been explored in clinical trials for COVID-19 to counter hyperinflammation.
Despite promise, challenges remain, including optimizing antibody specificity, minimizing off-target effects, and understanding tissue-specific CD24 expression patterns. Ongoing studies aim to refine CD24-targeted biologics for broader therapeutic applications.
×
